



OPEN ACCESS

EDITED AND REVIEWED BY
Michael P. Lisanti,
University of Salford, United Kingdom

*CORRESPONDENCE
Ryan C. Gimple
✉ ryangimple@gmail.com

RECEIVED 03 August 2023
ACCEPTED 23 August 2023
PUBLISHED 07 September 2023

CITATION
Gimple RC, Prager BC and Xie Q (2023)
Editorial: Epigenetic and metabolic
regulation of primary and
metastatic brain cancers.
Front. Oncol. 13:1271851.
doi: 10.3389/fonc.2023.1271851

COPYRIGHT
© 2023 Gimple, Prager and Xie. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Editorial: Epigenetic and metabolic regulation of primary and metastatic brain cancers

Ryan C. Gimple^{1*}, Briana C. Prager² and Qi Xie^{3,4,5}

¹Department of Medicine, Washington University School of Medicine, Washington University in St Louis, St. Louis, MO, United States, ²Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, United States, ³Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China, ⁴Westlake Laboratory of Life Sciences and Biomedicine, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China, ⁵Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China

KEYWORDS

brain cancer, cancer, epigenetics, metabolism, metastasis, tumor microenvironment, primary brain cancer, brain cancer stem cells

Editorial on the Research Topic

[Epigenetic and metabolic regulation of primary and metastatic brain cancers](#)

Primary intrinsic brain tumors and brain metastases are among the most lethal of all human malignancies despite decades of scientific advances. The intersecting fields of cancer epigenetics and metabolism lie at the core of our current conceptual framework for the pathophysiology of these diseases (1, 2). While alterations in epigenetic pathways contribute to neoplastic metabolic dysregulation through transcriptional control mechanisms, metabolite abundance and availability reciprocally impinge upon epigenetic pathways. In this Research Topic, we highlight important advances focused on epigenetic and metabolic processes that enable brain tumors to thrive within the intracranial setting, along with key insights into the tumor microenvironment.

Epigenetic pathways integrate multiple sources of information regarding cell state and microenvironmental features to orchestrate an organized cellular response, mediating cellular adaptability, plasticity, and resilience. In this Research Topic, [McCornack et al.](#) discuss mechanisms by which histone methyltransferases and acetyltransferases mediate these diverse processes including reviewing downstream signaling elements and therapeutic targeting opportunities. Valproic acid is a commonly used anti-epileptic with anti-tumor effects through its histone deacetylase (HDAC) activity; however, in this Research Topic, [Barciszewska et al.](#) define a new epigenetic role for valproic acid in the induction of global hypermethylation. This study provides a rationale for the combination of valproic acid with temozolomide for enhancing DNA damage and oxidative stress in glioblastoma tissues. Although extrachromosomal circular DNA (eccDNA) had been originally observed nearly six decades ago (3), the relevance of this alternative mechanism of dynamic gene regulation to cancer survival and therapeutic resilience has only recently come into sharper focus (4, 5), particularly in brain tumors (6–9). [Zhu et al.](#) interrogate the landscape of eccDNAs in medulloblastoma, showing preferential inclusion

of genes involved in neuronal development and differentiation, RAS GTPase binding, and RAP1 signaling. They further identify the upregulation of genes via eccDNAs associated with poor prognosis in clinical datasets, highlighting eccDNAs as important mediators of medulloblastoma pathophysiology and implicating future therapeutic targets.

Tumor metabolism impinges on multiple key oncogenic processes through the coordination of signaling cascades, bioenergetics, and structural components both in a cell-intrinsic manner and in the coordination of cellular interactions within the brain tumor microenvironment. [Bezawork-Geleta et al.](#) review the importance of lipid metabolism in glioblastoma biology, focusing on lipid droplets as key substrates for cellular energy production and as intermediates that affect cellular signaling through affecting ferroptosis (a lipid peroxidation mediated and iron-dependent form of cell death), and lipophagy (a lipid specific form of autophagy). Autophagy is a finely tuned cellular process that enables cancer cell survival in nutrient- and energy-poor settings that define the tumor microenvironment, but can also be exploited for anti-cancer therapies (10). Induction of cytotoxic autophagy using the small molecule inhibitor ABTL0812 impairs glioblastoma stem cell proliferation and stem features *in vitro* and displays combinatorial efficacy in orthotopic xenograft models when combined with standard-of-care radiotherapy and temozolomide, primarily through inhibition of AKT/mTORC1 signaling and activation of ER stress responses ([Mancini et al.](#)). These studies highlight the important metabolic adaptations utilized by primary brain tumors to survive in the intracranial setting and suggest a new approach to undermining these key dependencies.

Epigenetic and metabolic pathways further support tumor cell invasion. The blood-brain barrier preserves the integrity of the central nervous system and shields against toxins from the central circulation and from invading cancer cells. Breaching the blood-brain barrier is a critical step in the metastatic cascade responsible for the generation of brain metastases (11). [Zhang et al.](#) identify that the blood-brain barriers of patients with advanced lung cancers are more permeable than those of patients with early-stage lung cancers or healthy controls, suggesting that primary lung cancers may act at a distance to disrupt the blood-brain barrier and set the stage for future metastases. Further understanding of the processes underlying blood-brain barrier disruption may yield strategies to protect the brain from metastatic colonization. Meningiomas are among the most common primary brain tumors with widely variable prognoses based on molecular classification and morphologic features. [Jiang et al.](#) utilize imaging characteristics from MRI studies to improve the identification of the extent of tumor invasion to facilitate improved extent of resection. This study further identifies imaging features that serve as independent risk factors for predicting WHO tumor grades through deeper scrutiny of interactions within the brain-tumor interface.

This Research Topic further touches on therapeutics in the intracranial setting. Vasogenic edema is a major source of morbidity and mortality in intracranial malignancies with limited treatment

options (12). While studies have shown the efficacy of bevacizumab in reducing edema and progression-free survival in primary brain tumor patients (13, 14), [Bai and Zhou](#) investigate the role of bevacizumab in patients with lung or colon brain metastases, showing differential effectiveness based on the tumor of origin. The prognosis for patients with brain metastases from non-small cell lung cancer remains dismal, particularly when patients are not candidates for surgical resection due to a variety of patient or tumor characteristics. [Yang et al.](#) study the use of an alternative radiation therapy delivery modality, 125-Iodide brachytherapy, compared to external beam radiotherapy (EBRT) and find improved 6-month survival and similar 12-month survival for the 125-iodide group compared to the EBRT group. This study provides further evidence for an additional modality for the treatment of brain metastases.

In a prescient and well-timed review, [Johanssen et al.](#) describe the current state of basic and translational research as it applies to glioblastoma with a discussion of the importance of understanding brain tumors through the lens of intratumoral heterogeneity and within the context of their tumor microenvironments. They suggest the use of both rationally designed and hypothesis-generating unbiased combinatorial screening approaches that incorporate heterogeneous tumor models as well as important microenvironmental features to identify compounds and combination therapies with the greatest clinical utility. Taken together, this Research Topic highlights some of the latest advances in the fields of brain tumor biology, specifically focused on the intersection between cancer epigenetics and metabolism and touching on key elements of the tumor microenvironment, with an eye towards improving outcomes for patients with primary and metastatic brain tumors.

Author contributions

RG: Writing – original draft, Writing – review & editing. BP: Writing – original draft, Writing – review & editing. QX: Writing – original draft, Writing – review & editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Izzo LT, Affronti HC, Wellen KE. The bidirectional relationship between cancer epigenetics and metabolism. *Annu Rev Cancer Biol* (2021) 5:235–57. doi: 10.1146/annurev-cancerbio-070820-035832
2. Dai Z, Ramesh V, Locasale JW. The evolving metabolic landscape of chromatin biology and epigenetics. *Nat Rev Genet* (2020) 21:737–53. doi: 10.1038/s41576-020-0270-8
3. Cox D, Yuncken C, Spriggs AI. Minute chromatin bodies in Malignant tumours of childhood. *Lancet* (1965) 1:55–8. doi: 10.1016/s0140-6736(65)90131-5
4. Yi E, Chamorro Gonzalez R, Henssen AG, Verhaak RGW. Extrachromosomal DNA amplifications in cancer. *Nat Rev Genet* (2022) 23:760–71. doi: 10.1038/s41576-022-00521-5
5. Hung KL, Mischel PS, Chang HY. Gene regulation on extrachromosomal DNA. *Nat Struct Mol Biol* (2022) 29:736–44. doi: 10.1038/s41594-022-00806-7
6. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature* (2017) 543:122–5. doi: 10.1038/nature21356
7. deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. *Nat Genet* (2018) 50:708–17. doi: 10.1038/s41588-018-0105-0
8. Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, et al. Functional enhancers shape extrachromosomal oncogene amplifications. *Cell* (2019) 179:1330–1341 e1313. doi: 10.1016/j.cell.2019.10.039
9. Nathanson DA, Gini B, Moghadeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. *Science* (2014) 343:72–6. doi: 10.1126/science.1241328
10. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer* (2017) 17:528–42. doi: 10.1038/nrc.2017.53
11. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. *Nat Rev Cancer* (2020) 20:26–41. doi: 10.1038/s41568-019-0205-x
12. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. *Nat Rev Clin Oncol* (2009) 6:229–36. doi: 10.1038/nrclinonc.2009.14
13. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med* (2014) 370:699–708. doi: 10.1056/NEJMoa1308573
14. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med* (2014) 370:709–22. doi: 10.1056/NEJMoa1308345